This article is more than 5 years old. Information may no longer be current.
Six updates in pediatric dermatology: Researchers identify AD biomarkers in children, more
Click Here to Manage Email Alerts
Researchers discovered a method to evaluate the cutaneous biomarkers of atopic dermatitis using minimally invasive tape strips, which may offer insight into tracking pediatric treatment responses in the future, in the top pediatric dermatology story at Healio.
See below for links to new guidelines in pediatric psoriasis, declining melanoma rates, Taltz efficacy in young patients with psoriasis and more.
Tape strip approach identifies atopic dermatitis biomarkers in children
“We have therapeutic development moving into children, and we also need biomarkers to understand treatment responses in children,” study author Emma Guttman-Yassky, MD, PhD, of the department of dermatology and laboratory for inflammatory skin diseases, Icahn School of Medicine at Mount Sinai Medical Center, told Healio Dermatology. “Up until now, we couldn’t do anything because you can’t take biopsies in children. No one would even consider it.” Read more.
Experts publish ‘comprehensive’ pediatric psoriasis guidelines
The new guidelines from the American Academy of Dermatology and the National Psoriasis Foundation are the first of its kind to focus on pediatric psoriasis, according to Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology at University of Pennsylvania Perelman School of Medicine. Read more.
Melanoma rates decline among US adolescents, young adults
“We do not know why these trends are occurring; however, we hypothesize that public health campaigns and messaging aimed at promoting sun protection in childhood may be shaking out to have an impact on decreasing melanoma incidence in adolescents and young adults,” Jennifer M. Gardner, MD, assistant professor in the division of dermatology at University of Washington, told HemOnc Today. Read more.
Taltz improves skin, itch, QoL in pediatric patients with psoriasis
Phase 3 data presented at the European Academy of Dermatology and Venereology Congress demonstrated that treatment with Taltz resulted in a 75% improvement in Psoriasis Area of Severity Index score and static Physician Global Assessment of clear or almost clear skin at 12 weeks in pediatric patients with moderate to severe plaque psoriasis. Read more.
Dupixent improves eczema severity in adolescents
Findings from a phase 3 clinical trial support the use of weight-based Dupixent dosing in adolescents with moderate to severe atopic dermatitis. Read more.
Expert: Propranolol is gold standard in infantile hemangiomas
The common historical approach of “wait and see” for infantile hemangiomas can lead to bad outcomes, according to Lawrence A. Schachner, MD, a dermatologist and pediatrician. Read more.